The oncogenic role of SIRT2 has been identified in basal-like breast cancer cells and hepatocellular carcinoma 27, 37, and the interruption of SIRT2 catalytic activity was reported to potentially target a subset of c-Myc-driven cancers 38. This evidence concerns the gene MYC and breast cancer.